



SU-5402

Data Sheet

| | | | |
|-----------------------------|-----------------------------------|---------------------------|--|
| Catalog Number: | MC11113 | Product Type: | Small Molecule |
| Bio-Activity: | FGFR Phosphorylation inhibitor | CAS #: | 215543-92-3 |
| Research Categories: | Stem cells, cancer | Chemical Name: | 3-[4-Methyl-2-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]-propionic acid |
| Solubility: | Soluble in DMSO (up to 10 mg/ml). | Molecular Formula: | C17H16N2O3 |
| Purity: | > 98% | Molecular Weight: | 296.32 |
| Format: | Powder | Ship Temp: | Ambient |
| Storage: | -20°C | | |

Application Notes

Description/Data:

Inhibits FGFR phosphorylation in vitro, in cell culture [1], and in mouse tumor cell models [2]. SU-5402 can suppress ECP induced cardiomyocyte differentiation of P19CL6 embryonic carcinoma cells via an FGFR3 dependent pathway [3].

References:

- 1) Lee et al. (2013), Interleukin-1 β enhances cell migration through AP- κ 1 and NF- κ B pathway dependent FGF2 expression in human corneal endothelial cells; *Biol. Cell*, epub ahead of print Jan. 18 2013
- 2) Paterson et al. (2004), Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma; *Br. J. Haematol.*, 124 595
- 3) Jin et al. (2012), Eosinophil cationic protein enhances cardiomyocyte differentiation of P19CL6 embryonal carcinoma cells by stimulation the FGF receptor signaling pathway; *Growth Factors*, 30 344

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012